| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).
|
Eur J Endocrinol
|
2004
|
2.25
|
|
2
|
Hippocampal dysfunction in cured Cushing's syndrome patients, detected by (1) H-MR-spectroscopy.
|
Clin Endocrinol (Oxf)
|
2013
|
1.43
|
|
3
|
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
|
J Clin Endocrinol Metab
|
2012
|
1.24
|
|
4
|
The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics.
|
Eur J Endocrinol
|
2011
|
1.13
|
|
5
|
Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome.
|
J Clin Endocrinol Metab
|
2009
|
1.06
|
|
6
|
Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire.
|
J Clin Endocrinol Metab
|
2005
|
1.05
|
|
7
|
Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors.
|
J Clin Endocrinol Metab
|
2009
|
1.03
|
|
8
|
Acromegaly Quality of Life Questionnaire (AcroQoL).
|
Health Qual Life Outcomes
|
2004
|
1.00
|
|
9
|
Mapping CushingQoL scores onto SF-6D utility values in patients with Cushing's syndrome.
|
Patient
|
2013
|
0.97
|
|
10
|
Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing's syndrome.
|
J Clin Endocrinol Metab
|
2011
|
0.93
|
|
11
|
Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database.
|
J Clin Endocrinol Metab
|
2002
|
0.93
|
|
12
|
Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL).
|
Clin Endocrinol (Oxf)
|
2005
|
0.92
|
|
13
|
Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort.
|
J Clin Endocrinol Metab
|
2014
|
0.90
|
|
14
|
A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome.
|
Clin Endocrinol (Oxf)
|
2012
|
0.88
|
|
15
|
Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H).
|
J Clin Endocrinol Metab
|
2004
|
0.86
|
|
16
|
Clinical consequences of Cushing's syndrome.
|
Pituitary
|
2012
|
0.86
|
|
17
|
Rab18 is reduced in pituitary tumors causing acromegaly and its overexpression reverts growth hormone hypersecretion.
|
J Clin Endocrinol Metab
|
2008
|
0.84
|
|
18
|
Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA).
|
Pituitary
|
2013
|
0.84
|
|
19
|
Treatment of acromegaly improves quality of life, measured by AcroQol.
|
Clin Endocrinol (Oxf)
|
2007
|
0.84
|
|
20
|
A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly.
|
J Clin Endocrinol Metab
|
2009
|
0.83
|
|
21
|
Ghrelin is produced by and directly activates corticotrope cells from adrenocorticotropin-secreting adenomas.
|
J Clin Endocrinol Metab
|
2006
|
0.83
|
|
22
|
Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice.
|
Eur J Endocrinol
|
2012
|
0.83
|
|
23
|
Expression of functional KISS1 and KISS1R system is altered in human pituitary adenomas: evidence for apoptotic action of kisspeptin-10.
|
Eur J Endocrinol
|
2010
|
0.82
|
|
24
|
Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome.
|
J Bone Miner Res
|
2009
|
0.82
|
|
25
|
Biochemical and quality of life responses to octreotide-LAR in acromegaly.
|
Pituitary
|
2014
|
0.81
|
|
26
|
Impaired decision-making and selective cortical frontal thinning in Cushing's syndrome.
|
Clin Endocrinol (Oxf)
|
2014
|
0.81
|
|
27
|
Psychometric evaluation of the Cushing's Quality-of-Life questionnaire.
|
Patient
|
2013
|
0.80
|
|
28
|
Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
|
J Clin Endocrinol Metab
|
2010
|
0.79
|
|
29
|
Telomeres and endocrine dysfunction of the adrenal and GH/IGF-1 axes.
|
Clin Endocrinol (Oxf)
|
2013
|
0.78
|
|
30
|
Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study.
|
J Clin Endocrinol Metab
|
2014
|
0.78
|
|
31
|
Quality of life in patients with pituitary tumors.
|
Curr Opin Endocrinol Diabetes Obes
|
2009
|
0.78
|
|
32
|
Voltage-dependent Na+ channel phenotype changes in myoblasts. Consequences for cardiac repair.
|
Cardiovasc Res
|
2007
|
0.78
|
|
33
|
Perception of health and cognitive dysfunction in acromegaly patients.
|
Endocrine
|
2014
|
0.77
|
|
34
|
Immediate and delayed postoperative morbidity in functional and non-functioning pituitary adenomas.
|
Pituitary
|
2012
|
0.77
|
|
35
|
Pituitary tumors: coping with ‘cured’ pituitary tumors.
|
Nat Rev Endocrinol
|
2011
|
0.77
|
|
36
|
Quality of life in patients with hypopituitarism.
|
Curr Opin Endocrinol Diabetes Obes
|
2015
|
0.76
|
|
37
|
Growth hormone should be used only for approved indications.
|
J Clin Endocrinol Metab
|
2013
|
0.76
|
|
38
|
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study.
|
Clin Endocrinol (Oxf)
|
2014
|
0.76
|
|
39
|
[Telomeres, aging and Cushing's syndrome: are they related?].
|
Endocrinol Nutr
|
2012
|
0.75
|
|
40
|
Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing's syndrome.
|
J Clin Endocrinol Metab
|
2013
|
0.75
|
|
41
|
Soluble TNFα-receptor 1 as a predictor of coronary calcifications in patients after long-term cure of Cushing's syndrome.
|
Pituitary
|
2015
|
0.75
|
|
42
|
PATIENTS' PERCEPTION ON CLINICAL OUTCOME AND QUALITY OF LIFE AFTER A DIAGNOSIS OF CUSHING SYNDROME.
|
Endocr Pract
|
2015
|
0.75
|
|
43
|
Twelve years of the Spanish acromegaly registry: a historical view of acromegaly management in Spain.
|
Endocrinol Nutr
|
2010
|
0.75
|
|
44
|
[Neuroendocrinology in 2011].
|
Endocrinol Nutr
|
2012
|
0.75
|
|
45
|
Cinacalcet for management of hypercalcemia secondary to calcium-sensing receptor mutation.
|
Endocrinol Nutr
|
2012
|
0.75
|
|
46
|
[Role of health-related quality of life in clinical practice: subjectivity in evidence].
|
Endocrinol Nutr
|
2009
|
0.75
|
|
47
|
[Therapeutic value of growth hormone].
|
Med Clin (Barc)
|
2008
|
0.75
|
|
48
|
Cortisol Excess and the Brain.
|
Front Horm Res
|
2016
|
0.75
|
|
49
|
Endoscopic surgery in the skull base unit: experience in the first 72 cases.
|
Acta Otorrinolaringol Esp
|
2013
|
0.75
|
|
50
|
Genetic analysis does not confirm non-classical congenital adrenal hyperplasia in more than a third of the women followed with this diagnosis.
|
Hormones (Athens)
|
2014
|
0.75
|
|
51
|
Health-related quality of life in primary and secondary adrenal insufficiency.
|
Expert Rev Pharmacoecon Outcomes Res
|
2014
|
0.75
|
|
52
|
Quality of life in Cushing's syndrome.
|
Pituitary
|
2015
|
0.75
|
|
53
|
Cost of clinical management of acromegaly in Spain.
|
Clin Drug Investig
|
2012
|
0.75
|
|
54
|
Adrenal insufficiency and adrenal replacement therapy. Current status in Spain.
|
Endocrinol Nutr
|
2013
|
0.75
|